. In autoimmune disease-where the immune system mistakenly attacks host tissue-antibodies that reduce inflammatory cues improve the selectivity and effectiveness of treatments for diseases such as multiple sclerosis (MS) and rheumatoid arthritis.
Despite these advances, clinical translation still relies on costly, inefficient trial-and-error methodologies. Furthermore, existing animal models are often not predictive of human disease, leading to failure of late stage trials. In infectious disease, Novavax's vaccine for RSV-a respiratory virus impacting children and elderlylacked efficacy during a phase III trial (NCT02608502). In cancer, Juno's engineered T cell therapy for leukaemia was paused twice following patient deaths in phase II trials 3 . Meanwhile, in autoimmunity, Biogen's MS therapy, Opicinumab, missed efficacy endpoints in phase II 4 , while Circassia's cat allergy therapy failed in phase III (NCT01620762). Some of these trials failed because of efficacy, while others encountered safety issues that trials with smaller patient cohorts missed. Both shortcomings emphasize that the way vaccines and immunotherapies are developed-first in cells and animals, then in humans-does not provide a complete picture of how these technologies will perform in humans. Engineered immune tissues could help fill in these gaps by serving both as tools to study and diagnose immune disease, and as next-generation vaccines and immunotherapies with new capabilities.
Engineered immune tissues as tools and therapeutics
In this Review, we first highlight the major immune tissues, then discuss efforts to build immune organoids or organs-on-a-chip as tools, to reprogramme the function of existing immune tissues, and to design immune tissues for implantation as vaccines and immunotherapies. As tools, these technologies are significant in several ways. First, engineered immune tissues integrating human cells in culture could provide a more accurate research niche compared with 2D human cultures or pre-clinical mouse models that poorly recapitulate human immunity. Second, engineered immune scaffolds could support proliferation and analysis of rare immune populations isolated from patients. Watching these cells develop in a controlled human niche ex vivo might reveal new insights into pathologies that are difficult to study in patients, or enable renewable sources for blood cell production. Last, engineered immune tissues allow control over stromal components and extracellular cues-such as antigens, cytokines and mechanical properties. This control could help isolate links to differentiation and function of specific immune cell subsets.
Beyond use as tools, engineered immune tissues could serve as next-generation clinical options. A major challenge in the vaccine and immunotherapy field is targeting lymph nodes and the spleen-organs that coordinate and expand immune cells. This challenge could be bypassed by engineering implantable lymph nodes pre-primed against a particular pathogen or seeded with specific immune cell subsets. These designer tissues could be valuable in many translational contexts: generating durable responses against infectious disease, eliminating the requirement of ex vivo expansion before reinfusion of immune cells during adoptive cell cancer therapy, or programming immune cells to develop regulatory functions that control inflammation or autoimmunity. Engineered generative immune tissues or primary lymphoid organs-such as bone marrow (BM) or thymus-could create accurate humanized animal models. Such hosts could make clinical trials safer and improve understanding of cell behaviour in patient samples that are currently only detectable in vivo. For example, 3D structure and defined stromal cues have recently allowed engraftment of tumours from cancer patients in humanized mice that do not engraft using simple cell infusions 5 . As summarized in Table 1 , below we discuss exciting possibilities to leverage engineered immune tissues, highlight key hurdles that remain to be addressed, and provide comparisons to existing clinical options and emerging technologies.
Distinct organs control immune cell development
Immune cells develop in the BM and thymus-the generative or primary lymphoid organs (PLOs), then migrate to lymph nodes (LNs) and the spleen-the secondary lymph organs (SLOs). In SLOs, immune cells are activated against specific pathogens or molecules, then migrate back to the blood and sites of infection, cancer or disease (Fig. 1) . These migration patterns reveal that immune cells programmed in a distinct organ-such as LNs or the spleencan migrate throughout the host to initiate responses that are both systemic and specific.
In the BM, haematopoietic stem cells (HSCs) develop into common precursors that differentiate to the immune cells populating the body. Common myeloid precursors give rise to antigen presenting cells (APCs), including macrophages and dendritic cells (DCs) , that survey blood and tissue for foreign molecules 6 . A common lymphoid precursor gives rise to T and B lymphocytes in the BM that display receptors reactive against specific peptide fragments of degraded pathogens ('antigens') ( Fig. 1a) . T and B cells are key players in adaptive immunity owing to immunological memory that enables these cells to mount potent, highly specific and fastacting responses against pathogens. The large majority of B cells develop and exit the BM, migrating to LNs and the spleen until activated (Fig. 1a) . A small population of B cells that strongly bind self-antigens-which could lead to autoimmune disease, are deleted or undergo receptor editing to reduce self-reactivity (Fig. 1a ) 7, 8 . T cell precursors exit the BM and migrate to the thymus for positive and negative selection. These processes ensure T cells display the Thymus Thymic microenvironments on-a-chip depend on biochemical and mechanical cues from matrix and other cells. [25] [26] [27] Bone marrow Engineered bone marrow niches can be designed to ensure cellular diversity. 28, 30 Study immune cell interactions using organ on-a-chip as a tool Lymph node Immune cell directionality and velocity depend on ECM adhesion ligand presentation, matrix pore size and immune cytokine gradients. [35] [36] [37] [38] [39] Microfluidic devices can be used to study individual immune cell interactions. 40, 41 LN on-a-chip tools can be used to spatially resolve cues to control or study immune cell function. 42 Biomaterials to reprogramme the structure and function of existing immune tissues
Recruit and reprogramme immune cells using implantable scaffolds
Lymph node Implantable scaffolds with inflammatory cytokines, tumour antigens and danger signals recruit and activate DCs to leave the scaffold to prime efficacious anti-tumour T cells in LN. 44, 45 Injectable, porous scaffolds can be used to recruit and expand DCs in situ, promoting a stimulatory or regulatory environment depending on the signals and form of antigen presentation within the scaffold. 46, 47 Control local immune tissue function by implanting depots at the tissue site
Lymph node
Reprogramming the local LN environment using diffusion-limited particle depots loaded with immune cargo causes changes in the composition and function of both local and distal LNs, promoting inflammatory or regulatory systemic responses. 55, 56, 58 Control T cell development in vivo using artificial antigen presenting cells Lymph node Ellipsoidal artificial antigen presenting cells activate antigen-specific T cells more effectively, and have reduced non-specific uptake and clearance compared to spherical aAPCs. 61, 62 Artificial APCs loaded with antigen and co-stimulatory danger signals can be combined with additional molecules to enhance their ability to activate efficacious antigen-specific T cells in vivo. Alginate gels with stimulatory particles and tumour-specific T cells placed near solid tumours or resection sites effectively deliver tumour-specific T cells and promote inflammatory tumour-specific T cells against tumour escape variants better than cell injections 69, 70 Use 9, 10 . Mature T cells then migrate to the LN and the spleen.
Generation of antigen-specific T and B cell responses requires correct presentation of an antigen matching the specificity of the receptors on the T or B cell (that is, a 'cognate' antigen). Antigen is processed and displayed by APCs in LNs and the spleen after free antigen drains from skin or peripheral tissue, or after APCs in the periphery collect antigen and migrate to LNs or the spleen (Fig. 1c) . Additionally, the spleen removes foreign material from bloodsuch as bacteria, providing systemic antigen surveillance (Fig. 1c) 
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. (Fig. 1d) . Following activation, the chemokine receptors on T cells change to support migration of T cells back to the periphery to fight infection in sites displaying the antigen to which they have been primed. Cytotoxic T lymphocytes directly destroy infected host cells to prevent viral replication, while helper T cells secrete supportive signals, such as cues that trigger destruction of phagocytosed bacteria (Fig. 1c) . B cells produce low-affinity antibodies when B cell receptors are directly crosslinked by the antigen. Highaffinity antibody production requires B cells to interact with helper T cells (Fig. 1d) . This step initiates a cascade by which B cells form specialized domains in LNs-germinal centres (GCs)-where they interact with follicular DCs (FDCs) and helper T cells (Fig. 1d ) 13, 14 . In GCs, B cells undergo class switching and affinity maturation, processes that result in differentiated B cells called plasma cells. These cells secrete high-affinity antibodies that neutralize and tag pathogens for destruction (Fig. 1c) . Some of the B cells developed in GCs become long-lived memory B cells that enable rapid response against future infections 13 .
immune organoids and organs-on-a-chip 2D cultures have limited ability to recapitulate the immune interactions in the body. These models over-simplify the host environment using simplified cell subsets, extracellular matrix features, fluid flows and mechanical forces. 3D microenvironments that better mimic tissue structure can be created using organoids seeded with stem cells or heterogeneous cell populations, or using microfabrication to design well-defined organs-on-a-chip 15, 16 . Both of these approaches are being extended to immune organs-LNs, thymus and BM-to create tools to elucidate immune cell interactions and the link to immune response and disease. This work has already identified matrix porosity, fluid flow, cytokine expression and stromal cell interactions as important design parameters [17] [18] [19] [20] [21] .
Recapitulating organ-level immune function with organoids.
Recently, Purwada et al. generated immune organoids to create GC-like structures using porous hydrogels reinforced with nanoparticles to match the stiffness of natural SLOs (Fig. 2a ) 22, 23 . B cells were encapsulated in these gels, along with fibroblasts transduced to express two important B cell survival and activation signals (CD40L, BAFF) (Fig. 2b) 
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. This approach allowed B cells to develop phenotypic markers, such as GL7, indicative of GCs (Fig. 2c) . Further, the mechanical properties of the gel impacted formation of a stromal organoid network and the expression levels of the activation signals. 3D organoids-but not 2D approaches-promoted a 100-fold increase in naive B cell proliferation and differentiation to a GC phenotype (B220 + Fas + GL7 + ) (Fig. 2d) . Antibody class switching to IgG1 and IgE isotypes also occurred in the organoids; these antibodies promoted phagocytic destruction of pathogens and provided protection in mucosal tissues, respectively (Fig. 2e ) 22, 23 . While class switching is one important process in GCs, these organoids have not yet integrated secretion of antigen-specific antibodies or affinity maturation; the latter generates antibodies that strongly bind their cognate antigen. As such capabilities are integrated into LN organoids, these technologies will be increasingly useful for in vitro study or diagnosis of GC pathologies-such as B cell malignancies-through seeding organoids with patient cells. Engineered SLOs might further allow for more realistic in vitro assessment of vaccine performance by determining which antigen and adjuvant combinations maximize antibody affinity. There are also opportunities to generate fundamental insight; for example, LN organoids recently revealed the role of control pathways involved in unconstrained cell proliferation characteristic of GCs 24 . In addition to SLOs, thymus and BM organoids are being developed by seeding scaffolds with stem cells or other progenitors. As generative tissues, thymus and BM organoids could provide insight into immune cell development, and how these environments malfunction during diseases that cause deficient or self-reactive immune cells. Models of the thymus, where T cell selection occurs, have confirmed that 3D structure, ligand composition, and scaffold dimensions all impact function [25] [26] [27] . Similarly, BM organoids-where many immune cells and precursors are generated-are influenced by 3D structure and mechanical properties such as scaffold stiffness and extracellular matrix (ECM) porosity [28] [29] [30] . Kotov and colleagues developed a BM model from porous 3D colloidal crystals seeded with HSCs and human BM stromal cell lines 28 . Compared with 2D cultures, 3D constructs enhanced differentiation of HSCs to B cells. These cells matured and secreted antigen-specific antibodies upon stimulation with inactivated virus. While this work did not test how strongly the antibodies bind target antigens, the studies make clear that 3D structure and a small number of defined cell populationsthree in this case-can mimic some of the key processes of B cell development.
Natural BM microenvironments are enormously complex. Thus, in contrast to the approaches above using defined cell populations, other engineered BM niches are exploring scaffolds populated with heterogeneous mixtures of cell types and stromal cues. Torisawa et al. prepared a poly(dimethylsiloxane) (PDMS) device loaded with demineralized bone powder, collagen and bone-inducing factors (BMP-2, BMP-4) 30 . This device was implanted subcutaneously in mice and cultured for eight weeks to populate the BM niche before excision (Fig. 3a,b ). After removal, the engineered BM construct was inserted in a microfluidic device (Fig. 3c) , allowing maintenance of B cells, T cells, and myeloid cells in proportions characteristic of natural mouse BM for at least one week (Fig. 3d ). This in vitro niche mimicked responses of lymphoid cells to radiation when compared to responses observed in irradiated mice (Fig. 3e) .
Functional tests-such as the radiation response just mentioned-are important in pushing engineered immune tissues forward. Most reports seek to confirm an immune cell population of interest develops, or replicate a particular native immune process. Much less frequently are data reported that are relevant to the end-goal of diagnosis or therapy. Thus, translational applications of engineered immune tissues could directly accelerate clinical progress. For example, BM constructs could be used to screen for radiation toxicity and countermeasures in vitro as above, or to generate red blood cells for transfusions. Blood donations are limited by supply and compatibility. As one solution, synthetic blood that carries oxygen has been explored, but these carriers have limited capacity, lack cell function and could trigger host inflammatory responses 31 . Stem cells and immortalized cell lines have demonstrated promise in animals and in one human volunteer, but these cultures do not produce cells at acceptable quantities or costs [32] [33] [34] . Since 3D structure appears to improve performance of engineered BM niches, exploiting this idea might create viable options for large-scale blood production.
On-a-chip tools to study immune cell interactions. Beyond recreating organ-or tissue-level function in culture, new strategies are employing on-a-chip designs that harness microfabrication for precision control over the interactions of distinct immune cells or with defined extracellular signals. Considering the strong spatially governed nature of immunity (see Fig. 1 ), immune cell migration is a key area of study for these technologies. For example, the migration of both APCs and lymphocytes are being probed through perturbations in adhesion molecule type and concentration 35 , polymer scaffold composition and mechanical properties 36 , and fluid flow or cytokine gradients [37] [38] [39] . Additionally, real-time quantitative analysis of APC and T cell interactions-which mimic those occurring in SLOs-is helping to isolate the roles of T cell receptor binding affinities and valencies in controlling T cell activation 40, 41 . Hybrid devices integrating aspects from organoids and organson-a-chip are also being developed to study immune function. As one illustration, Ross et al. designed a strategy to place live LN slices in a perfusion chamber equipped with a microfluidic injector 42 . This approach allowed introduction of fluorescent probes and model therapeutics to distinct LN microdomains with spatial and temporal control. Such approaches could be useful in initiating, perturbing or blocking specific processes-such as GC reactions-or T cell egress from LNs during activation. However, the ability to generate functional responses to immune cues, and how well those responses mimic native LN processes have not yet been addressed.
reprogramming existing immune tissues in animals
In this section, we highlight studies aimed at reprogramming the structure and function of existing host immune tissues. One approach exploits 3D scaffolds to recruit and prime immune cells that then migrate back to SLOs to direct the function of these tissues. Another strategy uses direct injection of micrometre-scale depots into LNs to retain modulatory immune cues in these sites and reprogramme the local microenvironment. Last, we discuss efforts to expand T cells using particles that mimic the function of APC without reliance on stromal cues present in SLOs.
Scaffolds to recruit immune cells and direct SLO function.
Traditional vaccines are designed to drain or be carried to SLOs, where APCs and lymphocytes cooperate to generate adaptive responses to antigens in the vaccines. In contrast, biomaterial scaffolds are now being used to mimic the immunogenicity of natural infection environments by recruiting and activating APCs that subsequently return to SLOs to programme the specific features of immune responses arising in these tissues 43 . One application of particular interest for these scaffolds is cancer vaccines, which contain fragments of tumours in an effort to generate potent and selective anti-tumour immune responses. Because tumours are composed of host cells, a challenge for cancer vaccination is the difficulty of generating a large number of tumour-specific T cells. These cells must also remain functional despite the local immune-suppressing tumour environment. Toward addressing these challenges, early scaffolds were implantable structures loaded with tumour lysate as an antigen, granulocyte macrophage colony-stimulating factor (GM-CSF) as a signal to recruit APCs, and CpG as a stimulatory adjuvant 44, 45 . This approach increased DC recruitment to scaffolds in mice, allowing these cells to encounter tumour lysate and become activated. The tumour antigen-presenting DCs migrated back to LNs and greatly expanded tumour-specific T cells. As a result, expanded CD4
+ and CD8 + T cells infiltrated tumours at much higher levels (Fig. 4a) , ultimately clearing established tumours in an aggressive melanoma model.
More recently, surgical implantation has been eliminated using scaffolds that gel or self-assemble upon injection. Kim et al. used mesoporous silica rods (MSRs) to incorporate model antigens (ovalbumin; OVA), GM-CSF, and CpG (Fig. 4b ) 46 . The MSRs create an environment to recruit DCs by spontaneously assembling into scaffolds, enhancing both migration of tumour-primed DCs to LNs (Fig. 4c ) and survival in mice (Fig. 4d) . These effects required the scaffold component. Additionally, MSR scaffolds generated superior antibody responses in mice compared to the vaccine adjuvant, alum 46 . Recruiting APCs to implanted scaffolds could be useful in several translational contexts, including infectious disease and cancer, or to promote immune tolerance by omitting stimulatory signals 47 . Controlling APC activation and antigen loading to subsequently direct the function of T cells generated in LNs might also eliminate ex vivo manipulation during adoptive transfer cancer therapies. Adoptive therapies require isolating patient T cells, engineering the cells ex vivo, then reinfusing the cells back to the patient. Eliminating the ex vivo processing would dramatically decrease cost and complexity. However, realizing these possibilities using scaffolds will require more clinically relevant models and comparisons. Further, cancer vaccines are not administered as monotherapies, but in combination with resection, checkpoint blockade or other therapies. Thus, new materials approaches should be tested against or in combination with existing clinical regimens.
Another important direction in the biomaterials field centres on non-tissue engineering strategies for vaccines and immunotherapies, such as nanoparticles that drain to SLOs to direct responses to a foreign antigen [48] [49] [50] [51] [52] . This goal overlaps with some of the goals of engineered immune tissues-for example, generation of a response to a foreign antigen by implanting an engineered SLO pre-primed with the antigen. Similarly, the APC-recruiting scaffolds discussed for cancer vaccines could be compared with injectable nanodiscs that have recently generated exciting results in aggressive mouse cancer models using personalized tumour antigens 53 , or against new peptide-antibody conjugates exploited in models of melanoma and breast cancer 54 . Benchmarking tissue engineering approaches against nanoparticle technologies that target similar immunological goals could create frameworks for earlier assessment of parallel technologies, and identify where each approach provides distinct advantages.
Diffusion-limited depots to reprogramme the LN environment.
Another emerging strategy to control immune tissue uses degradable polymer depots injected directly to LNs to reprogramme the LN microenvironment. This approach leverages microparticles too large to drain from LNs, allowing mechanical retention of depots in LNs. Local controlled release of adjuvant from these particles increases adjuvant persistence in LNs, quickly and potently expanding antigen-specific T cells in mice 55 . These responses are much higher than adjuvant-loaded nanoparticles or free adjuvant, both of which drain out of LNs more quickly. While the added complexity makes this approach less appealing for traditional prophylactic vaccination, as a tool intra-LN depots offer opportunities to directly control the kinetics and combinations of signals in LNs to study immune cell function. For example, release of defined doses of regulatory cues in LNs during vaccination reveals the role of local concentration in polarizing antigen-specific T cells between suppressive, inflammatory and memory functions 56 . Several clinical trials have used ultrasound-guided injection of free peptides into LNs to investigate tolerance induction for allergies (NCT01982474) and type 1 diabetes (NCT01536431) 57 . Tostanoski et al. recently combined intra-LN injection with microparticle depots to combat autoimmunity by encapsulating a modulatory immune signal, rapamycin (Rapa), with a peptide self-antigen, myelin oligodendrocyte glycoprotein (MOG), that is attacked during MS 58 . A single injection of these depots into LNs of mice during a model of MS (Fig. 5a ) at the peak of disease permanently reversed disease-induced paralysis (Fig. 5b) . This reversal was MOG-specific, as OVA-loaded depots conferred no therapeutic effect (Fig. 5c) . Furthermore, the composition and structure of treated LNs and distant, untreated LNs both exhibited reorganization and increased regulatory T cells (Fig. 5d) . In the CNS-a location far from the treated node, inflammatory cell infiltration was reduced, correlating with reduced paralysis (Fig. 5e) 
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. This work showed that reprogramming the local environment of distinct LNs can promote tolerance that is systemic and myelin-specific. Thus, understanding the parameters to induce desired structures and functions in LNs can also enable control over immune function in other tissues.
Despite the feasibility of intra-LN administration in clinical trials, implementing this approach involves some unique considerations that may highlight its advantages. First, treatments for autoimmune disease involve non-specific suppression of excess inflammation accompanying these diseases with small molecules drugs and, more recently, monoclonal antibodies. These treatments-such as methotrexate, fingolimod, natalizumab and rituximab-provide patients with real gains, but cause off-target effects resulting from lack of selectivity. Monoclonal antibodies, for example, can target specific receptors but do not differentiate between expression of these receptors on normal and self-reactive cells. Thus, intra-LN reprogramming may be beneficial if more selective tolerance is demonstrated during direct comparisons to existing therapies. Second, while there are a number of injectable nanoparticle strategies being explored to promote tolerance 50 , a distinction between these approaches and direct LN reprogramming is the distribution and dose of cargo (that is, local LN injection versus systemic injection). Therapies integrating immunosuppressive components to polarize immune cells may be safer or more effective if concentrated in LNs. For example, control over the cells developing in a target SLO after depot injection could enable the programmed cells to subsequently migrate to sites of disease while exposing only the patient's SLO to a local immunosuppressant dose. In contrast, systemic inflammatory conditions might benefit from conventional injections that distribute immunosuppressant throughout the patient.
Using artificial APCs to control T cell expansion in vivo.
Artificial APCs (aAPCs) aim to directly expand and control T cells. This approach involves nano-or microparticles that present co-stimulatory molecules and antigen to locally stimulate T cells in peripheral tissues without requiring priming in LNs 59 . Artificial APCs first gained attention to support adoptive transfer therapies 60 ; however, ex vivo cell handling is complex and expensive, motivating use of aAPCs to directly expand T cells in vivo. Altering aAPC shape to maximize contact with T cells 61, 62 and combining aAPCs with modulatory signals 63, 64 have both been used to enhance aAPC function. The potential to directly enhance T cell expansion in vivo using aAPCs is becoming more intriguing as the power of T cell therapy has emerged. For example, recently approved T cell gene therapies (Novartis, Kite) are on the order of US$500,000 per treatment because these therapies require expansion of patient cells ex vivo before reinfusion. Harnessing shape and molecular interactions to maximize valency and contact time could improve the efficiency of T cell expansion. aAPCs enabling this control might eventually allow T cell therapy to be carried out in patients without need for ex vivo expansion, greatly reducing treatment cost and preparation time. Another clinically relevant example is Provenge, the first approved DC vaccine, which relies on infusion of modified DCs to provide a modest survival increase for patients with advanced prostate cancer (NCT00065442). Future approaches using aAPCs as artificial DCs that efficiently expand tumour specific T cells against target antigens-such as prostate cancer antigens-might provide new opportunities to improve these therapies. As with the other emerging ideas above, aAPCs should be tested in combination with checkpoint blockade and other common components of cancer treatment plans 64 . 
Designing immune tissues for implantation
Perhaps the ultimate goal of immune tissue engineering is the implantation of designed tissues that promote or restore desired immune functions. Implantable LNs or other SLOs primed for a specific response might effectively clear infections or tumours-or regulate distinct inflammatory cells to combat autoimmune disease, without the hurdle of vaccines or immunotherapies reaching an existing SLO. On another front, engineering generative lymph organs-thymus and BM-might help correct immune deficiencies, improve BM transplants, relax donor-recipient matching requirements and enable more accurate humanized animal models to study immunity and disease.
Mimicking adaptive functions with engineered SLOs. Tissue engineered LNs and spleens are being investigated in mice using scaffolds formed from natural materials-such as decellularized LNs that retain ECM components 65 . Alternatively, more defined materials, including alginate and collagen 66 , provide easily controlled mechanical and chemical properties 43 . The inclusion of stromal components needed for artificial SLO function distinguishes constructs in this section from scaffolds for recruitment of immune cells in the previous section; the latter aim to prime APCs that return to existing SLOs.
In one approach decellularized mouse LNs were seeded with splenocytes from donor mice, then implanted into syngeneic (the same mouse strain) or allogeneic (a different strain) mice 65 . While functionality was not tested, the cells survived for at least 14 days and the implants did not induce host responses. Suematsu et al. developed LN-like organoids by loading 3D collagen sponges with a mouse thymic stromal cell line and activated primary DCs 66 . In mice, these constructs developed distinct B and T cell zones resembling those in natural SLOs (Fig. 6a) . These scaffolds also exhibited B cell proliferation and development of high endothelial venules, a tissue microdomain that enables immune cell entry from blood ( Fig. 6b) . The scaffold structure was important, as neither collagen gels nor synthetic sponges recruited cells as effectively. As a functional proof of concept, DCs loaded with a model antigen were used to generate antigen-specific responses in healthy recipient mice (Fig. 6c) . Subsequent retransplantation of the organoids into a second mouse lacking functional B and T cells (that is, SCID) . Donor mouse skin grafts are well-tolerated after four weeks by recipients with matched thymic organoid implants, while third party skin grafts are rejected. i, Schematic depicting development of leukemic humanized bone marrow (BM) model. Mice were irradiated, then infused with haematopoietic progenitor cells from leukemia patients in distinct risk groups, or implanted with calcium phosphate scaffolds containing human mesenchymal stromal cells (MSCs) 6-8 weeks before infusion with the leukemic patient samples. Scaffolds created an artificial BM niche that enabled engrafting of some risk groups that could not be engrafted using the infusion alone. Adapted from ref. 66 , Macmillan Publishers Ltd (a-c); ref. 69 , Macmillan Publishers Ltd (d-f); and ref. 73 , Elsevier (g,h).
resulted in migration of B cells to the spleen and BM of recipients. The immunocompromised hosts were then able to generate antigen-specific antibodies, indicating artificial SLOs restored at least some immune function (Fig. 6c) . Implantation also promoted B cell affinity maturation and, notably, memory T and B cells 67 . However, in all of these studies, donor mice required pre-injection of the model antigen before organoid implantation. A related approach eliminated the requirement of cell seeding onto the scaffolds by loading scaffolds with particles that release chemokines and cytokines to direct cell distribution and recruitment, as well as GC formation 68 . For artificial SLOs to have a direct translational impact as vaccines and immunotherapies, these strategies will ultimately need to be compared against or tested with current human options or emerging candidates. For example, as vaccines, the magnitude and duration of antibody and T cells responses induced by pre-primed implantable SLOs might be more long-lasting than conventional vaccines by establishing a local tissue niche. These comparisons could build understanding of potency and durability that lead to artificial SLOs able to protect against pathogens that are otherwise intractable using conventional vaccine technologies, such as HIV, hepatitis C and malaria. Similarly, in cancer, tumour-primed SLOs might serve as potent new cancer vaccines, but should be tested in tandem with common combination therapies (for example, checkpoint blockade or adoptive transfer), since most treatment plans are multipronged. In autoimmunity, artificial SLOs incorporating selfantigens and regulatory signals might provide a route to promote antigen-specific tolerance that selectively controls disease. However, comparison to approved immunosuppressants and monoclonal antibodies is needed since these therapies currently provide benefits to patients but are hindered by the lack of specificity. Using the best available pre-clinical animal models is also important for meaningful comparisons in pre-clinical studies.
One recent approach in a more translational cancer model assessed alginate scaffolds containing T cell binding domains and particles loaded with stimulatory T cell signals (Fig. 6d) 
69
. These scaffolds were seeded with engineered tumour-specific T cells, then implanted in mice. To mimic challenging clinical settings, the scaffolds were tested in an incomplete resection model of breast cancer and in an inoperable, disseminated model of ovarian cancer. Scaffolds containing particles with proliferative T cell signals greatly expanded tumour-specific T cells compared to other aggressive adoptive cell therapies using the same cells and signals, but without scaffolds (Fig. 6e) . The expanded T cells migrated to tumours and caused complete regression in both cancer models (Fig. 6f) . Subsequently, Smith et al. used a similar design to deliver tumourtargeting T cells displaying chimeric antigen receptors (CAR) 70 . In solid tumour models of pancreatic cancer and melanoma that are difficult to treat, scaffold-based delivery was critical to eradicate tumours and protect against relapse.
As is becoming apparent from the examples above, an important theme is the need for comparison of emerging technologies aimed at similar problems. For example, the T cell scaffolds above require ex vivo preparation and seeding in the scaffold before implantation; a parallel approach by the same lab uses injectable nanoparticles that can introduce CAR T cell genes into circulating T cells to clear leukaemia in mice at levels similar to adoptive transfer therapies 71 . Direct comparisons between emerging technologies-scaffolds versus nanoparticles in this case-could help reveal settings where each is most useful. Further, artificial SLO technology has not yet leveraged a number of ubiquitous tissue engineering tools. Some of these include rigorous mechanical characterization of stress, strain and fatigue, along with techniques to control structure and signal density with high precision, such as 3D printing and lithography. These capabilities are of particular importance since the LN, spleen, thymus and BM all have spatial microdomains with distinct functions and mechanical properties, yet none of the examples here integrate spatial control beyond simple porosity.
Engineered thymus to enable organ transplantation. As introduced above, the thymus is critical in T cell selection, deleting cells that strongly bind self-antigens. Thymic tissue engineering offers potential to combat autoimmune disease driven by self-reactive cells, or improve transplantation by eliminating recipient-or donor-reactive T cells without broad or permanent immunosuppression 72, 73 . Thymic epithelial cells (TECs) are important in thymic T cell recruitment and selection, as are the other stromal cell interactions, chemokines and ECM cues needed for development of mature T cells. Decellularized thymic tissue can be seeded with thymic-derived cells (including TECs) to mimic this environment, creating a simple thymic framework 72 . When implanted in athymic nude mice lacking T cells, the resulting scaffolds attract hematopoietic progenitors from BM that can produce naive CD4 + and CD8
+ T cells. To induce tolerance in transplanted tissue, Fan et al. combined decellularized thymic tissue scaffolds with thymic stromal cells containing TECs, fibroblasts, and BM-derived T cell progenitors (Fig. 6g) 
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. Implanting these organoids in athymic nude mice generated naive T cells that could migrate to SLOs and provide functional T cell support required for B cells to generate high affinity, antigen-specific antibodies. Mice with the implants also rejected skin allografts displaying non-self-antigen, indicating functional, antigen-specific T cell response. Importantly, however, when the organoids were instead designed with a mixture of TECs from donors and recipients, donor-derived skin grafts were accepted by the recipients, demonstrating immunologic tolerance (Fig. 6h) . Since the studies above used athymic mice which do not generate a host response, an important question is how this approach would translate to human transplants; mature T and B cells in the periphery would still be donor reactive. Perhaps some gains could be realized through generation of tolerized cells in the thymus, or combining such approaches with immunosuppression to limit peripheral donor-reactive cells. Engineered thymus may also have utility in treating patients with immunodeficiencies-where human thymus transplants are being investigated-to restore missing immune functions, such as the DiGeorge anomaly and severe combined immunodeficiency (SCID) 74 .
Engineered BM to support haematopoiesis and immunity. Implantable BM scaffolds loaded with stem cells or other progenitors that differentiate into functional immune populations could help treat immune deficiencies, blood cancers or self-antigen specific lymphocytes arising during autoimmunity. However, engineered BM in this therapeutic context shares many of the translational challenges discussed for thymus with respect to mature lymphocytes present in recipients with intact immune systems. While implantable BM niches may one day be used in humans, engineered constructs may be useful in the nearer term for diagnosis and therapeutics screening in vitro or in humanized animal models. Better understanding of how material properties impact BM scaffold function could lead to constructs that support efficient engraftment with fewer patient cells for screening, or that maintain viability of cells in the niches for longer intervals. These properties would be useful for diagnostic applications where patient cells are limited or particular phenotypes are rare. Already, scaffold stiffness and cell density have both been shown to impact differentiation of BM stromal cells encapsulated in collagen gels 75 , while mimicking the modulus and porosity of native BM improves HSC homing and retention in mice 76 . One study exploring the idea of distinct spatial domains within engineered immune tissues has used scaffolds mineralized externally to recreate the function of bone, and non-mineralized internally to provide features of the haematopoietic niche that enable cell engraftment 77 . These studies might help define parameters for constructs designed to screen responses of patient cells to therapeutics in humanized mice.
In addition to material design considerations, advancing engineered BM niches to clinical utility will require human cells. One emerging strategy to generate these humanized niches involves seeding scaffolds with human stromal and progenitor cells 5, [78] [79] [80] . Holzapfel et al. generated a BM mimic using polycaprolactone scaffolds coated with calcium phosphate and bone inducing factors (rhBMP-7) 78 . Scaffolds cultured with human mesenchymal progenitor cells were then implanted into mice lacking key components of the immune system (NSG mice). After ten weeks, these constructs mimicked many mechanical, cellular and biochemical features of human BM. During similar studies, mice were irradiated ten weeks after scaffold implantation, then infused with human HSCs. The humanized BM environment preferentially recruited and maintained these HSCs, enhancing human leukocytes, T cells and progenitor cells in the construct and the host BM.
Engineered BM may be particularly useful in studying or eventually treating hematopoietic diseases and malignancies. Several reports combine bone-forming scaffolds and human mesenchymal stem cells (MSCs) to engraft leukemic cells 5, 79, 80 . In one example, NSG mice were irradiated and infused with hematopoietic progenitor cells from acute myeloid leukaemia (AML) patients with distinct risks groups; alternatively, calcium phosphate scaffolds seeded with human mesenchymal stromal cells were implanted 6-8 weeks prior to injecting mice with AML cells (Fig. 6i ) 5 . Without scaffolds, only 43% of AML patient samples could be These signals could be included in a tissue engineering design to promote a specific type of lymphatic vessel or immune cell in target locations. e, Delivering lymphangiogenic factors using a scaffold could promote lymph vessel growth, allowing for delivery of immune cells, which could enhance wound-healing abilities of the scaffold. f, Antigen-presenting scaffolds could be used to influence both the degree of immune cell proliferation and the specific phenotypes that arise, properties shown to be a function of both antigen dose and antigen display density. Credit: printed with permission from © Fairman Studios, LLC.
engrafted; scaffolds, however, allowed engraftment and development of AML from 74% of the patient samples. Of note, scaffolds supported engraftment of some risk groups that simple infusions did not. Thus, 3D structure and tunable scaffold properties might improve study or diagnoses through faster, more robust engraftment of cancers from patients using these animal models to accurately mimic the human setting. While cancer is a key area for these tools, recent evidence reveals that patient-derived tumour grafts implanted in immunodeficient mice quickly lose resemblance to the patient tumour during selection pressures occurring in host animals 81 . Coupling patient grafts with engineered BM scaffolds might be useful in overcoming this divergence by recreating human immune selection pressures in humanized mice displaying human tumours.
Most of the work in this section focuses on the function of an organoid itself, but the physical connection of the organoids to the lymphatic system is another area that should be pursued. For example, lymphatic endothelial cells, fibroblasts and adiposederived stem cells have been incorporated in scaffolds comprised of fibrin or collagen I 82, 83 . When combined with lymphangiogenic factors, such as VEGF-C, or fluid flow, lymphatic endothelial cells in these constructs grow into lymphatic capillary networks in vitro 84 . Lymphatic vessels are vital for immune cell homing and surveillance, so controlling lymphangiogenesis in or around engineered immune tissues could increase antigen and immune cell recruitment to, or dissemination from, these sites.
New immunological insight informs immune engineering
In this section we highlight some recent immunological advances in fields distinct from tissue engineering that have important implications for engineering immune tissues. The ways in which this knowledge translates to design criteria for immune tissues, such as LNs, are presented in Fig. 7 .
Dynamic stromal cues in SLOs influence cell differentiation. The stroma provides distinct cues to attract and organize immune cells at different stages of response in LNs and spleen. These interactions are coordinated through the types of signals presented 85, 86 , as well as the locations [87] [88] [89] and timing 90 . Stromal cells, such as fibroblastic reticular cells, blood endothelial cells and lymphatic endothelial cells, can all present antigens to T cells 91, 92 . For example, Tamburini et al. found that after a viral infection or vaccination, lymphatic endothelial cells can proliferate and capture antigens, continuing to display the antigens for weeks 93 . In designing artificial LNs or spleen, this finding could be leveraged by incorporating lymphatic endothelial cells in constructs, along with T cell homing molecules, to provide prolonged antigen exposure and development of memory T cells (Fig. 7a) .
Immune cells actively interact with stromal cues, such as the distinctive compositions of ECM laminin fibres secreted by stromal cells. Warren et al. discovered that during immunity and inflammation, laminin α 4 decreases and laminin α 5 increases, while during tolerance, laminin α 4 increases and laminin α 5 decreases 94 . These changes alter the interactions of DCs and T cells to help promote either pro-immune or regulatory T cell responses. Thus, tissue engineering scaffolds could integrate specific compositions of laminins, or other stromal components, to direct tolerogenic or stimulatory responses (Fig. 7b) .
Matrix mechanical properties direct immune cell function.
Mechanical properties play an important role in controlling immune cell migration and function. Interestingly, new studies reveal that in natural LNs, ECM properties change over the course of immune response. In particular, fibroblastic reticular cells, which form the collagen network that enables immune cell trafficking, work with DCs to contract fibres during resting states, then relax the network during immunostimulatory conditions to accelerate cell mobility (Fig. 7c) 
95
. This discovery implies a potential route to enable 'ondemand' access of immune cells to specific signals at different stages of response by coupling collagen networks of different densities with defined concentrations of antigen and adjuvant.
Beyond SLO tissues, matrix mechanical properties are important in the tumour microenvironment, where immunosuppressive conditions severely limit immunotherapies. In addition to suppressive biochemical cues, tumours confront immune cells with rigid ECM environments that create high solid stress forces not encountered in healthy tissue 96 . This feature may impact immune cell function or deter infiltration in tumours; these stresses could be mimicked to limit or direct migration of immune cells to and within immune tissue scaffolds (Fig. 7c) .
Peripheral tissues alter immune cell homing and function.
Immune cells function and interact differently depending on their location within the body, making immune cell migration and homing critical for immune responses. These movements are directed partly by lymphatic endothelial cells displaying homing signals for specific sites 97 . For example, lymphatic vasculature comprises two vessel types-afferent vessels that bring antigens and leukocytes to LNs, and efferent vessels by which only lymphocytes and antigens can leave LNs. Iftakhar-E-Khuda et al. recently used gene expression to define molecular profiles differentially expressed on afferent and efferent lymphatic endothelial cells 98 . Designed immune tissues could exploit these molecular homing signals to recruit lymphocytes or promote rapid egress of activated T cells from LN during vaccination; conversely, constructs targeting autoimmunity or transplantation could display molecules that restrict immune cell egress (Fig. 7d) .
Beyond promoting or suppressing inflammatory functions, immune cell interactions with peripheral tissues influence wound healing for regenerative medicine applications. Thus, much effort in tissue engineering is directed at understanding pathways involved in inflammatory responses to design scaffolds that instead drive wound healing 99, 100 . One recent study revealed colony stimulating factor-1 in macrophages as a key pathway to prevent fibrosis-which often leads to failure of implants-without interfering with other macrophage functions 101 . In another example, Guc et al. showed the importance of inducing lymphangiogenesis-lymphatic vessel generation-to promote wound healing. Controlling the release of lymphangiogenic factors promoted lymphatic capillaries that regulated the levels of leukocytes delivered to diabetic wound sites, enhancing ECM deposition and healing (Fig. 7e) 
102
. This work highlights another important design consideration: implantable immune tissues could include factors to promote lymphangiogenesis to enhance recruitment or dissemination of lymphocytes (Fig. 7e) . Whether this approach might allow for direct connection with existing lymphatic vascular or SLOs-and how important this link is-are open questions.
Vaccine and immunotherapy design informs tissue engineering.
In tissue engineering, recent studies reveal that the choice of scaffold material itself can impact immune cell signalling 103 . This observation is in line with findings confirming many common biomaterials can directly activate the inflammasome and other innate stimulatory pathways through intrinsic material properties 104, 105 . Thus, physicochemical material properties (for example, charge, molecular weight, chemical functionality) may provide a new route to programme pro-immune or regulatory responses into scaffold frameworks used in engineered immune tissues. Furthermore, several new studies have taken quantitative approaches toward developing immunological design parameters that could be harnessed for scaffolds. These include the impact of antigen display density on immune response 106, 107 , and the role that specific types and ratios of stromal cells play in directing lymph node function, such as fibroblastic reticular cells 108 . For example, Singha et al. combined computational modelling, immunology and materials fabrication to show with molecular precision that changing the dose of self-peptide presented to self-reactive T cells during autoimmunity controls T cell expansion, while the phenotype of the expanding T cells is dependent on the density of the peptide complexes 107 . Recent studies have also shown density plays an important role in how an antigen is processed in APCs. Hess et al. discovered delivering the same total amount of self-peptide on particles at a low density was more effective in promoting tolerance than display at high density on fewer particles 106 . Thus, controlling the number and density of antigen on designed immune tissues-or in spatially distinct regions of these constructs-could help control the phenotypes of expanding cells (Fig. 7f) .
Outlook
While engineering functional, implantable immune tissues to restore or reprogramme immune responses is daunting, emerging immunological discoveries are bringing this vision closer. More realistic in vitro models and on-a-chip designs continue to improve our ability to interrogate basic immunological interactions. Combining this knowledge with emerging tissue engineering technologies could enable designer immune tissues that accelerate screening of candidate vaccines and immunotherapies, and that improve the success or robustness of vaccines and therapies targeting cancer, transplantation and autoimmunity.
